FibroBiologics says Australia accepts patent application for CBD adjuvant therapy in degenerative disc disease
FBLG•Patent application accepted in Australia
FibroBiologics says IP Australia accepted its patent application for cannabidiol as an adjuvant to fibroblast cell therapy in degenerative disc disease.
Application No. 2020368344 outlines treatment methods combining cannabidiol with fibroblast cells, including differentiated cells intended to support disc regeneration.
Claims also cover using cannabidiol to boost fibroblast regenerative activity, including higher growth-factor output such as IGF-1 or EGF-1.
